BlueCrest Capital Management’s NeoGenomics NEO Stock Holding History

BlueCrest Capital Management’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-10,295	Closed	-$84K	–	1703
2018 Q1	$84K	Buy	+10,295	New	+$83.4K	﹤0.01%	1386
2015 Q2	–	Sell	-93,149	Closed	-$435K	–	872
2015 Q1	$435K	Buy	+93,149	New	+$405K	0.02%	477

Other funds holding NEO

General Electric Evendale, Ohio $369M AUM 19.65% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

BlueCrest Capital Management's NEO Position: Q2 2018 in Review

BlueCrest Capital Management sold out of NeoGenomics (NEO) in Q2 2018, closing a stake of 10,295 shares — an estimated $84K sold.

BlueCrest Capital Management first reported a position in NEO in Q1 2015 and held it in 2 quarters. The position peaked at $435K in Q1 2015. 147 funds tracked by Wall St. Rank hold NEO as of Q2 2018.

BlueCrest Capital Management reported no remaining NeoGenomics position as of Q2 2018 after selling out during the quarter.
BlueCrest Capital Management sold 10,295 NeoGenomics shares in Q2 2018, an estimated $84K.
BlueCrest Capital Management first reported a position in NeoGenomics in Q1 2015 and held it in 2 quarters.
BlueCrest Capital Management's NeoGenomics position peaked at $435K in Q1 2015.
147 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.